Clinical Trials for Non-Small Cell Lung Cancer

A First-in-Human, Multicenter, Open-Label, Phase 1/2a Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET Amplified and c-Met Overexpressing Non-Small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with ECOG 0–1 and advanced c-Met–expressing solid tumors after standard therapy, with expansion cohorts emphasizing MET-amplified and/or c-Met–overexpressing nonsquamous NSCLC after prior platinum, immunotherapy, and targeted therapy when applicable. All patients receive CKD-703, a c-Met–targeted antibody–drug conjugate delivering the microtubule toxin MMAE.

ClinicalTrials.gov ID: NCT07439094

A Phase 1 Study of IM-1617 in Participants With Advanced Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with ECOG 0–2 and measurable, unresectable locally advanced or metastatic solid tumors, including colorectal cancer, NSCLC, breast cancer, and upper GI adenocarcinomas; expansion focuses on refractory colorectal cancer and NSCLC. All receive IV IM-1617, an antibody–drug conjugate targeting an undisclosed receptor tyrosine kinase and delivering the HC74 topoisomerase-I inhibitor payload.

ClinicalTrials.gov ID: NCT07578571

A Phase 1 Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SHY-ONC6 in Participants With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors that have progressed on, or are unsuitable or intolerant of, standard therapy receive once-daily oral SHY-ONC6. SHY-ONC6 is a small-molecule proteasome inhibitor targeting selected AAA+ ATPases in the 19S regulatory particle to disrupt ubiquitinated protein processing and promote apoptosis.

ClinicalTrials.gov ID: NCT07705334

A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory unresectable or metastatic solid tumors and an accessible injectable lesion, with expansion cohorts in cutaneous squamous-cell carcinoma, melanoma, head and neck squamous-cell carcinoma, NSCLC, and triple-negative breast cancer. Patients receive intratumoral N17350 every 2 weeks, a recombinant mutant porcine pancreatic elastase targeting the neutrophil elastase/ELANE pathway and designed to induce immunogenic tumor-cell death.

ClinicalTrials.gov ID: NCT07339176

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Enrichment, and Dose-Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BLU-924 (SAR449336) as Monotherapy and Combination Therapy in Participants With Advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Harboring KRAS Mutations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated metastatic pancreatic ductal adenocarcinoma, NSCLC, or colorectal cancer harboring KRAS G12C/D/V/A/S or G13D mutations, measurable disease, and ECOG 0–1 are eligible. Participants receive oral once-daily BLU-924 (SAR449336), an investigational pan-KRAS small-molecule inhibitor, as monotherapy.

ClinicalTrials.gov ID: NCT07629960

Phase I, Open-Label Study of Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells (TCR1188-ABC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HLA-A*11:01-positive, KRAS G12V-mutant metastatic pancreatic, biliary, colorectal, or non-small cell lung cancer after standard therapy receive fludarabine/cyclophosphamide lymphodepletion followed by a single infusion of autologous TCR-engineered T cells recognizing HLA-A*11:01-presented KRAS G12V and targeting ILT4/LILRB2-positive immunosuppressive cells; prophylactic tocilizumab is given on day 2.

ClinicalTrials.gov ID: NCT07594067

A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS02 in Participants With EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with EGFR-mutated locally advanced or metastatic NSCLC, measurable disease, and ECOG 0–1 receive oral ANS02 monotherapy. ANS02 is a fourth-generation, mutant-selective EGFR tyrosine kinase inhibitor targeting activating and resistance mutations, including T790M and C797S-containing mutants, while relatively sparing wild-type EGFR.

ClinicalTrials.gov ID: NCT07538804

A Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-DWJ155 and Safety and Imaging Properties of [68Ga]Ga-DWJ155 in Patients With Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced breast, non-small cell lung, gastric/GEJ, or bladder cancer lacking a suitable standard treatment undergo [68Ga]Ga-DWJ155 PET imaging; those eligible then receive intravenous [177Lu]Lu-DWJ155. This investigational HER2-targeted radioligand delivers localized beta radiation to HER2-expressing tumor cells.

ClinicalTrials.gov ID: NCT07660055

A Phase 1/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ARV-6723 Administered as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic solid tumors after prior immune-checkpoint or related T-cell-directed therapy and appropriate standard therapy may receive oral ARV-6723 alone or with pembrolizumab. ARV-6723 is an investigational PROTAC that degrades HPK1/MAP4K1 to enhance antitumor immune signaling; later cohorts may include investigator-selected standard of care.

ClinicalTrials.gov ID: NCT07749586

A Phase 1b/2 Study of ASP388B as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced unresectable or metastatic HNSCC, ESCC, mCRPC, squamous NSCLC, or SCLC receive ASP388B, an investigational antibody–drug conjugate with an undisclosed target, as monotherapy. Previously untreated recurrent/metastatic HNSCC or ESCC cohorts receive ASP388B with pembrolizumab and platinum/5-fluorouracil chemotherapy.

ClinicalTrials.gov ID: NCT07730021